Previous 10 | Next 10 |
A look at the top 10 most actives in the United States Kintara Therapeutics Inc. (KTRA) rose 63.3% to $0.164 on volume of 223,092,889 shares C3is Inc. (CISS) rose 24.2% to $0.0508 on volume of 148,576,579 shares Nikola Corporation (NKLA) fell 8.4% to $0.8918 on volume of 128,870,418 share...
2024-04-03 13:52:57 ET More on Tracon TRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Tracon Historical earnings data for Tracon Financial information for Tracon Read the full article on Se...
2024-04-03 13:15:01 ET H.C. Wainwright analyst issues BUY recommendation for TCON on April 3, 2024 12:15PM ET. The previous analyst recommendation was Buy. TCON was trading at $0.2835 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Curre...
ENVASARC Trial is Fully Enrolled and Final Data are Expected in Third Quarter 2024 SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP)...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 51.9% to $0.1549 on volume of 312,863,578 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.4% to $3.51 on volume of 229,852,079 shares SoundHound AI Inc. (SOUN) fell 3.2% to $8.37 on volu...
2024-03-05 22:37:19 ET TRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Conference Call March 5, 2024 16:30 ET Company Participants Charles Theuer - President & Chief Executive Officer Scott Brown - Chief Financial Officer Conference Call Participants ...
2024-03-05 16:04:24 ET More on Tracon Seeking Alpha’s Quant Rating on Tracon Historical earnings data for Tracon Financial information for Tracon Read the full article on Seeking Alpha For further details see: Tracon GAAP EPS of -$0.01 beat...
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other li...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other lif...
News, Short Squeeze, Breakout and More Instantly...
TRACON Pharmaceuticals Inc. Company Name:
TCON Stock Symbol:
NASDAQ Market:
TRACON Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Zoomcar Holdings Inc. (ZCAR) rose 58.3% to $0.2162 on volume of 130,087,791 shares Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.1863 on volume of 71,767,970 shares SMX (Security Matters) Public Limited Company (SMX) rose 17.1...
A look at the top 10 most actives in the United States Senti Biosciences Inc. (SNTI) rose 51.3% to $0.4175 on volume of 386,768,896 shares NVIDIA Corporation (NVDA) rose 0.6% to $124.3 on volume of 277,459,318 shares PROSHARES TRUST (SQQQ) fell 1.9% to $8.12 on volume of 139,088,335 share...
2024-07-01 12:15:02 ET H.C. Wainwright analyst issues NEUTRAL recommendation for TCON on July 1, 2024 11:46AM ET. The previous analyst recommendation was Buy. TCON was trading at $1.44 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...